Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue — Update
By Kosaku Narioka
Takeda Pharmaceutical reported a rise in first-quarter net profit as revenue climbed, driven by sales growth of key drugs and a weaker yen.
The Japanese drugmaker said Wednesday that net profit increased 6.5% from a year earlier to 95.25 billion yen ($623.4 million) for the three months ended June 30. That exceeded the estimate of Y53.24 billion in a poll of analysts by data provider Quick.
First-quarter revenue rose 14% to Y1.208 trillion, thanks to sales growth of several key products and a weaker yen. Sales of ulcerative colitis drug Entyvio climbed 22% to Y234.4 billion and sales of plasma-derived products increased 30% to Y271.4 billion.
Meanwhile, sales of Vyvanse dropped 6.9% to Y114.6 billion after Takeda lost U.S. market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year.
Its operating profit margin deteriorated to 13.8% from 15.9% a year earlier.
Takeda left its earnings forecasts unchanged for the year ending March 2025.
The company continues to expect revenue to rise 2.0% to Y4.350 trillion and net profit to fall 60% to Y58.00 billion this fiscal year.
Takeda said in May that it expected to book Y140.0 billion in restructuring expenses this fiscal year under a new growth and cost reduction initiative.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
July 31, 2024 03:19 ET (07:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks